ArticleSignal transduction and targeted therapy2020
Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2.
Article in Signal transduction and targeted therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination.Journal of translational medicine · 2026Article
- Heavy-chain immune repertoire sequencing enables language-model prediction of antigen-specific antibodies.Research square · 2026Article
- Fine-tuned protein language model identifies antigen-specific B cell receptors from immune repertoires.bioRxiv : the preprint server for biology · 2025Article
- Two cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting.Archives of virology · 2025Article
- Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses.Cell reports · 2024Article
- Article
- Comparative single-cell transcriptomic profile of hybrid immunity induced by adenovirus vector-based COVID-19 vaccines.Genes and immunity · 2024Article
- Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent.Pathogens (Basel, Switzerland) · 2024Article
- Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD.iScience · 2023Article
- Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern.iScience · 2021Article
- The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.Cell reports · 2021Article
- SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization.Cell discovery · 2021Article
- Immunodominant antibody germlines in COVID-19.The Journal of experimental medicine · 2021Article
- SARS-CoV-2 escapebioRxiv : the preprint server for biology · 2020Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.